Astodrimer, also known as SPL7013, a microbicide developed by Starpharm. This drug has been used in phase III clinical trials for the treatment and prevention of Bacterial Vaginosis. Starpharma conducts a meeting with US FDA related to potential approval of astodrimer in Bacterial vaginosis. In addition, SPL7013, participated in phase II clinical trials against human immunodeficiency virus (HIV) and herpes simplex virus 2 (genital herpes, HSV-2). It is known that astodrimer binds tightly to R5 gp120 in the gp120-CD4 complex, thus preventing the accrual of the requisite number of gp120-CD4 complexes across the virus-cell interface, thereby blocking virus entry.
Approval Year
PubMed
Subunit 0
Subunit 1
Subunit 2
Subunit 3
Subunit 4
Subunit 5
Subunit 6
Subunit 7
Subunit 8
Subunit 9
Subunit 10
Subunit 11
Subunit 12
Subunit 13
Subunit 14
Subunit 15